MedTrace Logo

Ezra Faster Scan Study

NCT05385718 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 694

Last updated 2025-03-03

No results posted yet for this study

Summary

The Ezra Faster Scan study uses non-invasive magnetic resonance imaging (MRI) technology that can "visually" detect early and late-stage cancer, and other pathologies. MRIs use a magnetic field and radio waves to create a 3-dimensional (3D) image of an individual's body without using ionizing radiation.

The purpose of this research is to decrease the amount of time required by an individual to complete an early cancer screening comprehensive magnetic resonance imaging (MRI) scan, such as the Ezra Full Body MRI imaging scan. If the time required to conduct a comprehensive scan is reduced, the cost of the scan may also decrease. By decreasing consumer costs and time, more individuals may be able to afford MRI-based early cancer screening technology.

Participants in this study will undergo a minimum 30-minute MRI session. These sessions will be used to evaluate new MRI "instructions" that allow for a faster MRI scan time. The images will also be used to develop mathematical models or machine learning tools that allow images to be enhanced. By enhancing images using machine learning, they may be restored to a quality typically observed in MRI sessions with longer scan (acquisition) times.

To read more about the study, potential participants may review the informed consent form located below in the References section. Potential participants may email [email protected], or call 516.340.1221.

See study Eligibility Criteria below.

Conditions

  • Medical Oncology
  • Cancer
  • Healthy

Interventions

OTHER

Magnetic Resonance Imaging

Participants are required to undergo a non-invasive magnetic resonance imaging (MRI) scan approximately 30 minutes in length.

Sponsors & Collaborators

  • Ezra AI, Inc.

    lead INDUSTRY

Principal Investigators

  • David Girard · Ezra AI, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2025-02-24
Completion
2025-02-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05385718 on ClinicalTrials.gov